(Peoples Daily Health Client reporter Chen Linhui) This weeks A -share market pharmaceutical biological sector listed company ushered in a dense disclosure period.In the same period, it increased by 73.22%, and Kexing Pharmaceuticals export revenue increased by 47%in the third quarter.increase.
Puli Pharmaceuticals "going to sea" in the third quarter of this year is excellent.According to the third quarter report released on October 28, revenue in the third quarter of this year increased by 22.9%year -on -year, and internationalized and synthetic creatures started a new journey.In the first three quarters, the company realized operating income of 625 million yuan, an increase of 0.34%over the same period last year. Among them, international business sales revenue increased by 65.89%compared with the same period last year. In the third quarter, international business sales revenue increased by 73.22%compared with the same period last year.
Internationalization of Prubi Pharmaceutical Products.Companys official website map
Kexing Pharmaceuticals overseas platform is accelerated, and the export revenue of Kexing Pharmaceuticals in the third quarter is 47%.According to the three quarters of the report, Koxing Pharmaceutical was driven by overseas commercialization, and its business operations improved. In the third quarter, overseas revenue was 59 million yuan.Overseas income.According to Kexing Pharmaceutical, white protein paclitaxel was approved by the European Commission in July this year, and obtained the British listing permit in October, further expanding its coverage in the global market.
The business growth in the third quarter of stable medical care has also gained a new turning point.According to the third quarter performance report released on October 28, in September this year, stable medical treatment acquired 75.2%of a medical consumables and industrial protection enterprises in cash.Filled the blank of the companys overseas capacity.
Gan Li Pharmaceuticals sales revenue in the third quarter increased by 72.1%year -on -year. According to the third quarter report released this year, in the first three quarters of this year, the companys emerging market expansion has achieved remarkable results, and international sales orders have increased.The international sales revenue was 242 million yuan, an increase of 37.63%year -on -year.
Kang Long turned into the first three quarters. Thanks to the gradual recovery of the needs of overseas customers, and more service items gradually entered the phase of clinical development in the middle and late stages, the companys new signing amount was year -on -yearGrowing more than 18%.
